The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase ...

Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit ...

The FDA’s Oncologic Drugs Advisory Committee voted against an application for Columvi (glofitamab) plus GemOx for ...

What's more, both FDA Commissioner Martin Makary, M.D., and longtime FDA oncology chief Richard Pazdur, M.D., have a new ...

The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma ...

Swiss healthcare company Roche (RHHBY) on Friday said that the European Medicines Agency’s Committee for Medicinal Products ...

After a median follow-up of 24.7 months, data showed a 40% improvement in overall survival (OS) for patients treated with Columvi (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin ...

The FDA's Oncologic Drugs Advisory Committee voted 8 to 1 against whether Genentech's pivotal trial is applicable to the US ...

Roche has secured approval from the European Commission (EC) for Columvi (glofitamab) plus gemcitabine and oxaliplatin (GemOx) combo to treat adults with relapsed or refractory (R/R) diffuse large ...

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall ...

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients – Updated data from the pivotal Phase III STARGLO study ...